Recruiting
Investigational
A Phase 3 Study of Orelabrutinib to Delay Disability Progression in Patients with Non‑Active Secondary Progressive Multiple Sclerosis
Investigational
- Substances:–
Countries:
Italy
Italy- Participants:18–64 years
Find therapies in clinical trials near you
- recruiting
- 3 962
- countries
- 28
- conditions
- 2 101
3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today
148 trials match your criteria
Recruiting
Renal disorder
RecruitingInvestigational
BI 764198 in Adults and Adolescents with Proteinuric Kidney Diseases
Investigational
- Disease:Renal disorder
- Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
Countries:Italy
Italy- Participants:0–17 years · 18–64 years · 65+ years
- Substances:[4-(6-Aminopyridazin-3-Yl)Piperidin-1-Yl][5-(4-Fluorophenoxy)-4-Methoxypyridin-2-Yl]Methanone
Recruiting
Cardiac failure+1
RecruitingInvestigational
Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity
Investigational
- Disease:Cardiac failureObesity
- Substances:–
Countries:Italy
Italy- Participants:18–64 years · 65+ years
Recruiting
Cardiovascular disorder+1
RecruitingInvestigational
Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk
Investigational
- Disease:Cardiovascular disorderHypertension
- Substances:ZILEBESIRAN
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:ZILEBESIRAN
Recruiting
Bronchiectasis
RecruitingInvestigational
Study of BI 1291583 tablets taken once daily for 76 weeks in adults with bronchiectasis
Investigational
- Disease:Bronchiectasis
- Substances:Bi 1291583
Countries:Italy
Italy- Participants:0–17 years · 18–64 years · 65+ years
- Substances:Bi 1291583
Recruiting
Crohn's disease
RecruitingInvestigational
Study of tulisokibart compared to placebo in adults with moderate to severe Crohn's disease
Investigational
- Disease:Crohn's disease
- Substances:Tulisokibart
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Tulisokibart
Recruiting
Colitis ulcerative
RecruitingInvestigational
Study on Eltrekibart and Mirikizumab for Adults with Moderate to Severe Ulcerative Colitis
Investigational
- Disease:Colitis ulcerative
- Substances:MirikizumabHumanised Igg4 Kappa Monoclonal Antibody Against Cxcl1, Cxcl2, Cxcl3, Cxcl5, Cxcl6, Cxcl7 And Cxcl8
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Mirikizumab
Recruiting
Acute myocardial infarction
RecruitingInvestigational
Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History
Investigational
- Disease:Acute myocardial infarction
- Substances:Selatogrel
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Selatogrel
Recruiting
Coeliac disease
RecruitingInvestigational
Study on ZED1227 for Improving Symptoms in Celiac Disease Patients on a Gluten-Free Diet
Investigational
- Disease:Coeliac disease
- Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Methyl (E,6S)-7-[[1-[2-(2-Ethylbutylamino)-2-Oxoethyl]-2-Oxopyridin-3-Yl]Amino]-6-[(3-Methylimidazole-4-Carbonyl)Amino]-7-Oxohept-2-Enoate
Recruiting
Hepatic fibrosis+2
RecruitingInvestigational
Study on Efruxifermin for Patients with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis
Investigational
- Disease:Hepatic fibrosisMetabolic dysfunction-associated steatohepatitis+1
- Substances:Efruxifermin
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Efruxifermin
Recruiting
Arteriosclerosis
RecruitingInvestigational
Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis
Investigational
- Disease:Arteriosclerosis
- Substances:Clazakizumab
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Clazakizumab
Recruiting
Hepatic cirrhosis+2
RecruitingInvestigational
Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Investigational
- Disease:Hepatic cirrhosisMetabolic dysfunction-associated steatohepatitis+1
- Substances:Efruxifermin
Countries:Italy
Italy- Participants:18–64 years · 65+ years
- Substances:Efruxifermin